Last reviewed · How we verify

Buprenorphine Transdermal Matrix Patch

Washington University School of Medicine · Phase 3 active Small molecule

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.

Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings. Used for Chronic pain management, Opioid use disorder maintenance treatment.

At a glance

Generic nameBuprenorphine Transdermal Matrix Patch
SponsorWashington University School of Medicine
Drug classPartial mu-opioid receptor agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management; Opioid Use Disorder
PhasePhase 3

Mechanism of action

Buprenorphine's partial agonist activity at the mu-opioid receptor produces a ceiling effect on respiratory depression, making it safer than full opioid agonists. The transdermal matrix patch formulation provides sustained, controlled release of buprenorphine through the skin, enabling prolonged dosing intervals and improved patient compliance compared to oral or sublingual formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: